Prognostic value of p16 promoter hypermethylation in colorectal cancer: a meta-analysis.
Cancer Invest
; 32(2): 43-52, 2014 Feb.
Article
en En
| MEDLINE
| ID: mdl-24410593
ABSTRACT
Whether or not p16 promoter hypermethylation has any prognostic value on the survival of patients with colorectal cancer (CRC) is uncertain. A meta-analysis was therefore conducted on the overall survival involving 16 studies with 3968 patients and disease-free survival involving six studies with 1091 cases, respectively. The promoter hypermethylation was found to be significantly associated with shorter survival compared to controls, which was not only stable according to influence analysis and cumulative meta-analysis but also conclusive according to trial sequential meta-analysis. The meta-analysis supports the hypermethylation as an independent adverse prognostic factor for CRC.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Colorrectales
/
Metilación de ADN
/
Genes p16
/
Proteínas de Neoplasias
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Cancer Invest
Año:
2014
Tipo del documento:
Article
País de afiliación:
China